Latest Clinuvel Pharmaceuticals (ASX:CUV) News

Page 2

Page 2 of 2

CLINUVEL Advances SCENESSE® for Adolescents with EPP, Reports Consistent Safety

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.

Victor Sage

10 Feb 2025